Latest news with #Exchange
Business Insider
20 hours ago
- Business
- Business Insider
Dangote highlights plans to rake in $70 billion and how it keys into listing his factories
The plan of Nigeria's richest man, Aliko Dangote, to list the Dangote Oil-Refinery and the Dangote Fertilizer Plant on the stock market is hardly news, as this idea continues to be touted. However, recent reports indicate that timelines have been stamped to go ahead with the initiative, particularly with the oil-refinery. Aliko Dangote plans to list his Nigerian oil refinery and fertilizer plant on the stock market, with the oil refinery's listing expected by 2026. Dangote Fertiliser Limited has received support for its intended market listing, aligning with its robust financial performance projections. The Dangote fertilizer plant is expected to generate significant daily revenues, attracting investors with dollar-denominated yields. Recently, Aliko Dangote announced plans to list his massive Nigerian oil refinery on the stock market by the end of 2026. Additionally, during a visit by capital market stakeholders to the company's facilities, Dangote announced plans to list Dangote Fertiliser Limited. In response, key capital investors and the Nigerian Exchange Group have made clear their intent to support Dangote Fertilizer Limited's intended listing on the Exchange. The financial viability of this decision was elaborated on by the CEO of the group, who highlighted key revenue figures and how they key into plans for the listings. He noted that the fertilizer facility, which now has plans for expansions, is expected to generate $20 million daily. 'With projected revenues of $20 million daily and a cumulative earning potential of $70 billion, this listing will offer investors dollar-denominated returns and long-term value,' he stated. As reported by the Punch, Temi Popoola, the NGX Group's Group Managing Director and CEO, indicated that the Exchange can raise funds for major initiatives. 'In 2024 alone, Nigerian investors deployed over N2tn into the banking sector. With Dangote Fertiliser's listing, we're poised to replicate this success, providing the infrastructure and liquidity to drive industrial growth,' he said. Jude Chiemeka, the Chief Executive Officer of Nigerian Exchange Limited, added that the listing will serve to show the Exchange's capacity to draw in large transactions. 'This listing will showcase NGX's ability to attract transformative deals. Our market's depth, transparency, and investor base ensure seamless execution,' Chiemeka said. $2.5 billion plan for the Dangote Fertilizer Plant As part of a larger plan to hasten the economic transformation of the continent, Nigerian billionaire Aliko Dangote has revealed plans to expand the $2.5 billion Dangote fertilizer plant. The goal of the project, which would greatly increase production capacity, is to improve agricultural input self-sufficiency and lessen Africa's excessive reliance on imported fertilizer. Africa currently imports over 6 million metric tons of fertilizer annually, a costly dependence that hampers agricultural productivity and exposes farmers to global supply shocks. According to Afreximbank's trade analysis, Africa's fertilizer exports in 2021 would be worth $8.9 billion, more than double the continent's imports of $3.7 billion—a surplus fueled mostly by North African manufacturers. Morocco and Egypt alone accounted for $6.23 billion in fertilizer exports, accounting for more than 70% of Africa's total and demonstrating the region's expanding importance in global supply chains. Dangote's facility, now one of the world's largest, can generate up to 3 million metric tons of urea each year.
GMA Network
2 days ago
- Business
- GMA Network
Lower stock trading tax takes effect July 1, 2025
Stock market investors and traders could look forward to increased earnings as the legislated cut in Stock Transaction Tax (STT) would take effect next month. In an advisory, the Philippine Stock Exchange Inc. (PSE) said the Republic Act No. 12214 or the Capital Markets Efficiency Promotion Act (CMEPA), which slashed the STT from 0.6% to 0.1%, would be in effect on July 1, 2025. With this, the PSE said that the STT of 'one-tenths of one percent (1/10 of 1%) shall apply to transactions through the Exchange made on July 1, 2025 onwards.' The STT is applied on the gross selling price or gross value in money of the shares of stock sold, exchanged, or disposed of. The reduced STT rate of 0.1% would mean that for every P1,000 of listed shares disposed or sold, the tax would be lower at P1, instead P6 under the previous rate. — BAP, GMA Integrated News
Cision Canada
4 days ago
- Business
- Cision Canada
NexLiving Communities Announces Adoption of Omnibus Equity Compensation Plan
HALIFAX, NS, June 25, 2025 /CNW/ - (TSXV: NXLV) – NexLiving Communities Inc. ("NexLiving" or the "Company") announced that at its annual general meeting held on June 4, 2025, shareholders of NexLiving approved the adoption of the Company's omnibus equity compensation plan (the "Plan") approved by the board of directors of NexLiving on May 2, 2025. The TSX Venture Exchange (the "Exchange") has provided conditional acceptance of the Plan, subject to the Company meeting all of the requirements of the Exchange. The Plan replaces the Company's amended and restated incentive stock option plan and amended and restated deferred share unit plan. The principal amendments to such predecessor plans are to allow for the issuance of stock options, stock appreciation rights, deferred share units, restricted share units and performance share units pursuant to the Plan. The purpose of the Plan is to attract and retain directors, officers, employees, consultants and management company employees of NexLiving and to motivate them to advance the interests of the Company by affording them with the opportunity to acquire an equity interest in the Company through security-based compensation awards which are exercisable or can be settled by the issuance of common shares of the Company. The aggregate number of common shares to be awarded under the Amended Plan will be a rolling maximum number that will not be greater than 10% of the issued and outstanding common shares at any point in time. Given 32,690,316 common shares are currently outstanding, 3,269,031 common shares will be reserved for issuance under the Plan, subject to adjustment upon any increase in the number of common shares outstanding. The rules and policies of the Exchange provide that a rolling plan must be approved by the shareholders every year. On June 24, 2025, the Board of Directors approved the issuance of 120,000 DSUs to directors and employees of the Company. The DSUs vest over three years in accordance with the provisions of the Company's omnibus equity compensation plan. About the Company NexLiving continues to execute on its plan to acquire recently built or refurbished, highly leased multi-residential properties in secondary markets across Canada. NexLiving aims to deliver exceptional living experiences to our residents and provide comfortable, affordable housing solutions that cater to a wide range of demographics. The properties offer a range of modern and updated suites, with a variety of amenities and features that allow residents to experience a hassle-free and maintenance-free lifestyle. NexLiving is committed to investing in its properties to ensure that they are modern and up to date. The Company currently owns 2,083 units in New Brunswick, Quebec, Ontario and Manitoba. NexLiving has also developed a robust pipeline of qualified properties for potential acquisition. By screening the properties identified to match the criteria set out by the Company (proximity to healthcare, amenities, services and recreation), management has identified a number of attractive acquisition targets. For more information about NexLiving, please refer to our website at and our public disclosure at Forward-Looking Statements This news release forward-looking information within the meaning of applicable Canadian securities laws (" forward-looking statements"). All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "projects", "estimates", "forecasts", "intends", "continues", "anticipates", or "does not anticipate" or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements contained in this news release include, but are not limited to, management's expectations of meeting all the requirements of the Exchange and issuing future security-based compensation awards pursuant to the Plan. Such forward-looking statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. These forward-looking statements reflect the current expectations of the Company's management regarding future events and operating performance, but involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual events could differ materially from those projected herein and depend on a number of factors. These risks and uncertainties are more fully described in regulatory filings, which can be obtained on SEDAR at under NexLiving's profile, as well as under Risk Factors section of the MD&A released on April 25, 2025. Although forward-looking statements contained in this new release are based upon what management believes are reasonable assumptions, there can be no assurance that actual results will be consistent with these forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this new release speak only as of the date of this news release. Except as required by applicable securities laws, the Company does not undertake, and specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Yahoo
4 days ago
- Business
- Yahoo
LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading On TSX Venture Exchange
Toronto, Ontario--(Newsfile Corp. - June 24, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce that, further to its news release of June 23, 2025, the Ontario Securities Commission (the "OSC") has revoked a Failure-to-File Cease Trade Order (the "FFCTO") that had been originally issued by the OSC against the Company on May 7, 2025. The Company is now current on its continuous disclosure obligations under securities legislation. As also previously announced, the Company is in the process of applying to the TSX Venture Exchange for reinstatement of trading in its common shares. A news release will be issued prior to the resumption of trading. About LevelJump Healthcare LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve. ON BEHALF OF THE BOARD OF DIRECTORS OFLEVELJUMP HEALTHCARE CORP. Mitchell GeislerChief Executive Officerinfo@ CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable). Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction. To view the source version of this press release, please visit
Yahoo
5 days ago
- Business
- Yahoo
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
WESTMINSTER, Colo., June 23, 2025--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy ("TriSalus" or the "Company"), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible Preferred Stock (the "Preferred Stock") identified in the Prospectus/Offer to Exchange (as defined below). TriSalus is committed to simplifying its capital structure and reducing the potential impact of dilution from its Preferred Stock. By exchanging outstanding shares of Preferred Stock for common stock, the Company eliminates complex capital layers and potential preferential claims, providing investors with a clearer view of the Company's equity value and improving transparency around ownership. What's Being Offered TriSalus is offering all holders of outstanding shares of Preferred Stock the chance to exchange their shares for common stock. Each share of Preferred Stock can be exchanged for common stock based on the total value it would accrue (including dividends through August 10, 2027), divided by $4.00 per share. In total, TriSalus is offering up to 11,860,206 shares of common stock to complete the exchange. Consent Solicitation: Proposed Change to Preferred Stock Terms Along with the exchange offer, TriSalus is asking preferred shareholders to approve an amendment to the Certificate of Designations of the Preferred Stock. If approved, this amendment would allow the Company to automatically convert all remaining Preferred Stock into common stock after the offer closes, based on a slightly lower exchange ratio (11.3% less than the current offer). Investors holding approximately 55% of the outstanding Preferred Stock have previously agreed to exchange their shares and approve the proposed changes pursuant to tender and support agreements. If the remaining conditions outlined in the Company's Prospectus/Offer to Exchange are met, these changes will go into effect. Key Dates and Information Deadline to Participate: The offer expires at 12:01 a.m. Eastern Time on July 23, 2025, unless extended. Preferred Stock holders can withdraw their tendered shares any time before the deadline. Offer Details The offer is described in full in the Prospectus/Offer to Exchange and Schedule TO, both filed with the U.S. Securities and Exchange Commission (SEC) on June 23, 2025. Common Stock Symbol: TLSI (traded on the Nasdaq Global Market); Preferred Stock: Not publicly traded; 3,594,002 shares outstanding as of June 13, 2025; Morrow Sodali LLC has been appointed as the Information Agent for the Offer and Consent Solicitation, and Continental Stock Transfer & Trust Company has been appointed as the Exchange Agent. Requests for documents should be directed to Morrow Sodali LLC at (800) 662-5200 (for individuals) or (203) 658-9400 (for banks and brokers) or via the following email address: TLSI@ About TriSalus Life Sciences TriSalus Life Sciences® is a growing, oncology focused medical technology business bringing disruptive drug delivery technology with the goal of improving therapeutic delivery for the treatment of both oncologic and non-oncologic conditions. Additionally, we are exploring the integration of our technology with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of liver and pancreatic indications. We have developed an innovative organ-specific platform that is designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) the immunosuppressive properties of liver and pancreatic tumor immune cells. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes. In partnership with leading cancer centers across the country – and by leveraging deep immuno-oncology expertise and inventive technology development – TriSalus is committed to advancing innovation that improves outcomes for patients. Learn more at and follow us on X (formerly Twitter) and LinkedIn. Important Additional Information Has Been Filed with the SEC The Offer described in this press release commenced on June 23, 2025. On June 23, 2025, a registration statement on Form S-4 and preliminary prospectus included therein (the "Prospectus/Offer to Exchange") and an exchange offer statement on Schedule TO (the "Schedule TO"), including an offer to exchange, a letter of transmittal and consent and related documents, were filed with the SEC by the Company. The offer to exchange the outstanding shares of Preferred Stock of the Company will only be made pursuant to the Prospectus/Offer to Exchange and Schedule TO, including related documents filed as a part of the Offer and Consent Solicitation. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROSPECTUS/OFFER TO EXCHANGE AND SCHEDULE TO FILED OR TO BE FILED WITH THE SEC CAREFULLY, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING THE EXCHANGE OFFER, INCLUDING THE TERMS AND CONDITIONS OF THE EXCHANGE OFFER. Investors and security holders may obtain a free copy of these statements (when available) and other documents filed with the SEC at the website maintained by the SEC at or by directing such requests to Morrow Sodali LLC at (800) 662-5200 (toll-free). Investors and security holders may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the "Investors" section of the Company's website at No Offer or Solicitation This press release shall not constitute an offer to exchange or the solicitation of an offer to exchange or the solicitation of an offer to purchase any securities, nor shall there be any exchange or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A registration statement on Form S-4 relating to the securities to be issued in the Offer has been filed with the SEC but has not yet become effective. Such securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The Offer and Consent Solicitation are being made only through the Schedule TO and Prospectus/Offer to Exchange, and the complete terms and conditions of the Offer and Consent Solicitation are set forth in the Schedule TO and Prospectus/Offer to Exchange. None of the Company, any of its management or its board of directors, or the Information Agent, the Exchange Agent or the Solicitation Agent makes any recommendation as to whether or not holders of shares of Preferred Stock should tender shares of Preferred Stock for exchange in the Offer or consent to the Preferred Stock Amendment in the Consent Solicitation. Forward-Looking Statements Certain statements made in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "become," "may," "intend," "will," "expect," "anticipate," "believe" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements may include, but are not limited to, statements regarding the consummation of the Offer and Consent Solicitation, the timing of the Expiration Date, the future effectiveness of the registration statement on Form S-4, the approval by the holders of shares of Preferred Stock of the Preferred Stock Amendment and subsequent entry into the Preferred Stock Amendment, the effects of the Offer on our capital structure and expected changes to the dilutive impact of the shares of Preferred Stock. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation: the Company's ability to successfully complete the Offer and Consent Solicitation; the number of holders of shares of Preferred Stock that approve the Preferred Stock Amendment in the Consent Solicitation; the timing and results of the SEC review of the registration statement on Form S-4 filed on June 23, 2025, if any; the Company's ability to attract and retain customers and expand customers' use of the Company's products; risks relating to market, financial, political and legal conditions; risks relating to the uncertainty of the projected financial and operating information with respect to the Company; risks related to future market adoption of the Company's offerings; risks related to the Company's marketing and growth strategies; risks related to the Company's ability to acquire or invest in businesses, products or technologies that may complement or expand its products, enhance its technical capabilities or otherwise offer growth opportunities; the effects of competition on the Company's future business; the risks discussed in the Company's quarterly report on Form 10-Q for the period ended March 31, 2025 under the heading "Risk Factors"; and the risks discussed in the Company's Registration Statement on Form S-4 filed on June 23, 2025, under the heading "Risk Factors" and other documents of the Company filed, or to be filed, with the SEC. If any of these risks materialize or any of the Company's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that the Company presently does not know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the Company's expectations, plans or forecasts of future events and views as of the date of this press release. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by applicable law. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. View source version on Contacts For Media Inquiries: Jeremy Feffer, Managing DirectorLifeSci Advisors917.749.1494jfeffer@ For Investor Inquiries: Dan GiordanoVice President, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
